Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06409832

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Headache Disorders Headache Disorders, Primary Headache Disorders, Secondary Migraine Disorders Migraine With Aura Migraine Without Aura Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi, Florence, Italy

Loading trial locations.

About this study

Rimegepant belongs to the gepants family, small molecules calcitonin gene- related peptide (CGRP) receptor antagonists. It is a new generation gepant, currently available as an orally disintegrating tablet at a single dose of 75 mg.

It has a double indication both for acute treatment for migraine with and without aura and preventive treatment of migraine. A previous randomized, placebo-controlled phase 2/3 trial demonstrated its effectiveness and tolerability in the preventive setting for patients with episodic and chronic migraine. Previous studies also demonstrated a good tolerability profile. The most commonly reported adverse events were nausea, nasopharyngitis, upper respiratory tract infections and urinary tract infections.

In this prospective multicentric study the investigators aim to evaluate rimegepant effectiveness and tolerability as preventive migraine treatment in a real-world setting. Subjects who meet the inclusion criteria will be enrolled and will participate in the study. Baseline demographic and clinical data will be collected at the baseline visit. The observation period will last for two years during which patients will take rimegepant 75 mg orally disintegrating tablet every other day for a time period related to eventual approval of reimbursability criteria.

Data will be collected at baseline and every three months for two years. Subjects will be asked to keep a headache diary to collect monthly headache and migraine days, migraine severity, associated symptoms and drug consumption. Questionnaires will be collected every three months.

Data collection will focus on: i) demographic data, ii) migraine history, iii) pain intensity, iv) presence and evolution of migraine associated symptoms and aura, v) migraine associated disability, vi) tolerability and eventual treatment- emergent adverse events, vii) treatment persistence, viii) questionnaires related to disability, allodynia, quality of life, interictal burden and effectiveness of the ongoing acute and preventive treatments. The online database REDCap will be used for data collection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
  • At least 4 monthly migraine days;
  • Good compliance to study procedures;
  • Availability of headache diary at least of the preceding months before enrollment.

Exclusion criteria

  • Subjects with contraindications for use of gepants;
  • Diagnosis of chronic migraine
  • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
  • medical comorbidities that could interfere with study results;
  • Pregnancy and breastfeeding.
  • Changes in preventive treatments in the month before the first administration of rimegepant

Treatment and study plan

Rimegepant 75 MG

Drug

Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention

Other names: Rimegepant

Primary outcomes

  1. Changes in migraine frequency after three months of treatment

    Time frame: Baseline (T0) - 3 months of treatment with rimegepant (T3)

    Changes in monthly migraine days after three months of treatment with rimegepant compared to baseline (continuous variable)

  2. Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant

    Time frame: Baseline (T0) - 3 months of treatment with rimegepant (T3)

    Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant

Secondary outcomes

  1. Changes in migraine frequency across twelve months of rimegepant treatment

    Time frame: Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Change of monthly migraine days after six and twelve months of treatment with rimegepant compared to baseline (continuous variable)

  2. Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) across twelve months of treatment with rimegepant

    Time frame: Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after six and twelve months of treatment with rimegepant

  3. Evaluation of any adverse event (qualitative)

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Type of any adverse events in patients receiving rimegepant during the observation period (categorical variable)

  4. Evaluation of any adverse event (quantitative)

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of reported adverse events in patients receiving rimegepant during the observation period (continuous variable)

  5. Evaluation of serious adverse event

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of serious adverse events (namely those resulting in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect) in patients receiving rimegepant during the observation period (continuous variable)

  6. Evaluation of adverse event leading to treatment discontinuation

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of adverse events leading to treatment discontinuation in patients receiving rimegepant during the observation period (continuous variable)

  7. Consistency of treatment response

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of patients with a stable 50% response during rimegepant treatment ( from 3 to 12 months of treatment) (continuous variable)

  8. Changes in migraine disability (MIDAS)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in MIgraine Disability ASsement questionnaire across rimegepant treatment (continuous variable, 0-270 scale, higher scores indicate higher disability: 0-5, little/no disability; 6-10, mild disability; 11-20, moderate disability; >20, severe disability)

  9. Changes in migraine disability (HIT-6)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in Headache Impact Test-6 questionnaire across rimegepant treatment (continuous variable, 36-78 scale, higher scores indicates greater disability)

  10. Changes in response to acute migraine treatment (m-TOQ)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in migraine Treatment Optimization Questionnaire across rimegepant treatment (continuous variable, 0-8 scale, higher score indicates higher acute therapy effectiveness)

  11. Changes in allodynia across rimegepant treatment (ASC-12)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in Allodynia Symptoms Checklist-12 questionnaire across rimegepant treatment (continuous variable, 0-24 scale, higher score indicates more severe allodynia)

  12. Changes in quality of life across rimegepant treatment (MSQ)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in Migraine Specific Quality of life questionnaire across rimegepant treatment (continuous variable, 0-100 scale, 100 indicates full functionality)

  13. Changes in interictal burden across rimegepant treatment (MIBS-4)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in Migraine Interictal Burden Scale-4 questionnaire across rimegepant treatment (continuous variable, 0-4 scale, 0 indicates no interictal burden, 1-2 mild level of interictal burden, 3 moderate interictal burden, 4 severe interictal burden)

  14. Percentage of patients with Medication overuse reverted during treatment

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of patients with a baseline diagnosis of MO reverted after 3 - 6 and 12 months of rimegepant treatment (continuous variable)

Other outcomes

  1. Changes in the number of monthly migraine days with aura (quantitative)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in the number of monthly migraine days with aura across rimegepant treatment (continuous variable, through headache diary assessment)

  2. Variation of duration of aura (qualitative)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in duration of aura across rimegepant treatment (categorical variable - minutes, assessed through headache diary)

  3. Variation of type of aura (qualitative)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in type of aura across rimegepant treatment (assessed through headache diary and anamnestic data collection)

  4. MMDs reduction in patients Non-responders to mAbs

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Change of monthly migraine days across rimegepant treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable)

  5. Percentage of 50% Responders in patients Non-responders to anti CGRP mAbs

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Percentage of 50% Responders across rimegepant treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable)

  6. Menstrually-related migraine

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Change in the number of menstrually-related attacks (according to ICHD-3) across rimegepant treatment compared to baseline (continuous variable)

  7. Change in self-reported effectiveness of rimegepant treatment

    Time frame: 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Change in Patients Global Impression of Change (PGIC) questionnaire across treatment (continuous variable, scale 0-7, 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse)

  8. Changes in migraine severity

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in migraine severity (continuous variable, 0-10 numerical rating scale, higher scores indicate higher severity)

  9. Changes in migraine duration across treatment

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in migraine duration across treatment (continuous variable, hours, assessed through a paper diary)

  10. Changes in duration of the most bothersome symptom(s)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in duration of the most bothersome symptom(s) (continuous variable, minutes, assessed through a paper diary)

  11. Changes in severity of the most bothersome symptom(s)

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in severity of the most bothersome symptom(s) (continuous variable: 0-10 numerical rating scale, higher scores indicate higher severity)

  12. Changes in self-reported effectiveness of acute treatment

    Time frame: Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

    Changes in self-reported effectiveness of usual acute treatment (Patients Global Impression of Change questionnaire across treatment: continuous variable, scale 0-7, 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse)

Study contacts

Contact information is provided by the study sponsor or research team.

Luigi F Iannone, MD

CONTACT

[email protected]

+393896969606

Roberto De Icco, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University of Florence

Other

Collaborators

  • A.O.U. Città della Salute e della Scienza
  • Asst Degli Spedali Civili Di Brescia
  • Auxologico San Luca
  • Azienda Ospedaliera S. Maria della Misericordia
  • Azienda Ospedaliero Universitaria Policlinico Modena
  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
  • Azienda Ospedaliero-Universitaria di Parma
  • Azienda Policlinico Umberto I
  • Cliniche Humanitas Gavazzeni
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
  • IRCCS National Neurological Institute "C. Mondino" Foundation
  • Ospedale Santo Stefano
  • Ospedale di Piove di Sacco
  • Società Italiana per lo Studio delle Cefalee
  • University of Campania Luigi Vanvitelli
  • University of Roma La Sapienza
  • Università degli Studi dell'Aquila

Registry information

Official study title

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)

Acronym: RAISE

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
May 10, 2024
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.